KnowHow: The FDB Blog

FDA's Biosimilar ID Requirements Fly in the Face of Cost-Cutting Aspirations

Corporate Perspective, Government, Standards
Friday, November 10, 2017 by Tom Bizzaro, RPh

Curiously, the FDA seems to be undercutting its own cost savings efforts through its support of a rule that would require unique non-proprietary names with four-character suffixes for biosimilar products. The problem is this proposed naming convention is simply not necessary and could do more harm than good. Read more...

Comments (0)
Pharmacists Comparing Labels

Drug Labeling Inconsistencies Abound Regarding Sulfites As Preservatives

Corporate Perspective, Information Systems
Tuesday, August 22, 2017 by Helena Dummler, PharmD

Our society’s focus on natural and organic products that promote health has directed scrutiny to chemicals used as preservatives. What is the issue with preservatives? Read more...

Comments (0)
Baseball sweet spot

Medical Device Data Transparency Could Help Health Systems Hit the Elusive Supply Chain "Sweet Spot"

Corporate Perspective, Transformational Change, Information Systems
Thursday, July 13, 2017 by Lee Ann McWhorter

Any baseball player will tell you how difficult it is to ensure that the ball hits the “sweet spot” on the bat. But their troubles pale in comparison to health system supply chain or value analysis committees. Read more...

Comments (0)
Innovation Bulb Illustration

Medication Adherence in the Safety Net: Where Simple Innovations Have Big Impact

Transformational Change, Information Systems
Tuesday, May 30, 2017 by Ray Pedden

They say, “Necessity is the mother of invention.” Nowhere is this truer than in the safety net where challenges are magnified by financial pressures, lack of resources and an unknown political landscape. The invention we see there is a far cry from the glamorous world of “think-tank” and “start-up” innovation. Instead, people have to come up with new and better ways of doing things just to get through the day. Read more...

Comments (0)
FDB Controlled Substances Blog Series Part 5

Pharmacists as Care Providers Just Makes Sense

Corporate Perspective, Transformational Change
Monday, May 8, 2017 by Nick Ratto, PharmD

The idea that pharmacists should act as care providers has been a part of the healthcare industry discourse for quite some time and has been steadily gaining momentum in recent years. Read more...

Comments (0)
View more

Don't Miss a Single Post!

Be notified about new FDB Blog posts as they are published by submitting the information below. (If you are already an FDB Customer in North America, you are automatically receiving blog updates by email and do not need to sign up.)

*
*
*

Blogger Spotlight

Tom Bizzaro

Tom Bizzaro, RPh
VP, Health Policy

Helena Dummler

Helena Dummler, PharmD
Clinical Pharmacist

Lee Ann McWhorter

Lee Ann McWhorter
Strategic Alliances Director

Ray Pedden

Ray Pedden
Strategy and Innovation, CCI

Nick Ratto

Nick Ratto, PharmD
Manager, Consumer Drug Info

Christine Cheng

Christine Cheng, PharmD
Clinical Pharmacist

Pat Lupinetti

Patrick Lupinetti, JD
Senior VP and Editorial Director

Brad Engels

Brad Engels
Associate Product Manager

Dewey Howell

Dewey Howell, MD, PhD
VP, Clinical Applications

Doris Yee, PharmD

Doris Yee, PharmD
Clinical Pharmacist